Dendreon Corporation  

(Public, NASDAQ:DNDN)   Watch this stock  
Find more results for DNDN
1.44
-0.08 (-5.26%)
After Hours: 1.44 0.00 (0.00%)
Sep 30, 6:34PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.44 - 1.52
52 week 1.24 - 3.52
Open 1.51
Vol / Avg. 0.00/2.08M
Mkt cap 243.68M
P/E     -
Div/yield     -
EPS -1.36
Shares 160.31M
Beta 2.61
Inst. own 36%
Nov 10, 2014
Q3 2014 Dendreon Corp Earnings Release (Estimated) Add to calendar
Aug 11, 2014
Q2 2014 Dendreon Corporation Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -18.57% -104.60%
Operating margin -2.03% -85.65%
EBITD margin - -54.78%
Return on average assets -16.02% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -

Address

SUITE 3200, 1301 2ND AVE.
SEATTLE, WA 98101
United States - Map
+1-206-2197815 (Phone)
+1-206-2560571 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).

Officers and directors

Douglas G. Watson Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
W. Thomas Amick President, Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Gregory R. Cox Interim Chief Financial Officer, Vice President, Treasurer
Age: 48
Bio & Compensation  - Reuters
William Monteith Executive Vice President - Technical Operations
Age: 56
Bio & Compensation  - Reuters
Lindsay Rocco Executive Vice President - Corporate Communications
Age: 35
Bio & Compensation  - Reuters
Andrew S. Sandler M.D. Executive Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
William Jenkinson Chief Marketing Officer, Vice President
Age: 43
Bio & Compensation  - Reuters
Robert L. Crotty Vice President, Interim General Counsel and Secretary
Age: 40
Bio & Compensation  - Reuters
Karen E. Brophy Vice President, Head of Human Resources
Age: 51
Bio & Compensation  - Reuters
Silvio Pacheco Vice President, Chief Customer Officer
Age: 48
Bio & Compensation  - Reuters